New Jersey Clinical Trials Report — May 2026

For New Jersey residents considering participation in clinical research, May 2026 presents a critical window of opportunity, particularly for those looking to join studies with impending enrollment deadlines. Across the state, a significant number of trials are slated to close within the next 90 days, meaning time is running out to explore these options. Individuals interested in contributing to medical advancements should act quickly.

A total of 109 clinical trials are nearing their conclusion in New Jersey. This urgency extends to healthy volunteers, with 15 of these rapidly closing studies actively seeking participants without specific health conditions. If you are a healthy individual looking to contribute to research, these opportunities require prompt attention before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, stroke recovery, and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Cervical cancer
• Breast cancer
• Pancreatic ductal adenocarcinoma
• Non-small cell lung cancer
• Ischemic stroke
• Ovarian cancer
• Sarcoma
• Endometrial cancer
• Head and neck cancer

New Research Opportunities Emerge in New Jersey

This month brings a select number of new trials to New Jersey, offering residents fresh avenues to engage with cutting-edge medical research. While the state saw 6 new trials open in May, this represents a notable decrease compared to the 25 trials that launched in April 2026, and a significant drop from 39 in March. Despite this, the new studies are impactful, including significant Phase 2 and 3 initiatives from major pharmaceutical companies and leading research institutions.

Among the notable new trials, several stand out for their scope and potential impact:

• Novo Nordisk A/S is sponsoring NCT07567001, a substantial Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with specific types of heart failure and excess body weight.
• Another significant trial is NCT07566988, a real-world study sponsored by Novartis Pharmaceuticals. This research aims to compare the effectiveness and economic burden of two existing treatments, ofatumumab and ocrelizumab, in 2,604 multiple sclerosis patients in the United States, utilizing administrative claims data.
• For healthy volunteers, Tarsus Pharmaceuticals, Inc. is conducting NCT07562087, a Phase 2 study designed to evaluate the safety, tolerability, and pharmacokinetics of TP-05 administered orally to 700 healthy adult participants with tick exposure. This offers a direct opportunity for individuals without specific conditions to contribute to research.
• Minerva Neurosciences is leading NCT07565428, a Phase 3 study to evaluate the efficacy and safety of Roluperidone in 380 adult subjects with negative symptoms and stable positive symptoms of schizophrenia. This trial also aims to assess the relapse rate of Roluperidone compared to antipsychotic medications.
• Memorial Sloan Kettering Cancer Center is sponsoring NCT07566377, a Phase 2 study investigating Cord Blood Transplantation as a treatment for children and young adults with blood cancer. This trial will enroll 71 participants.
• Additionally, NCT07560592, "The Salt Study for Heart Failure," sponsored by Maya Guglin, MD, seeks to understand the necessity of a low sodium diet for better health outcomes in 500 heart failure patients.

New Jersey's Research Footprint and Participant Demographics

New Jersey continues to be a hub for clinical research, with a total of 1,643 clinical trials currently recruiting across 164 cities and 1,078 research sites statewide. This broad distribution ensures accessibility for a diverse range of participants.

The 6 new trials opened this month are spread across several cities, including Basking Ridge, East Hanover, Elmer, Hackettstown, Haddon Heights, Marlboro, Marlton, Middletown, Montvale, and New Brunswick. This geographic spread indicates that research opportunities are not solely concentrated in major metropolitan areas but are available in various communities throughout the state.

Participation in clinical trials is open to a wide range of individuals. Of the new trials launched this month, 4 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is open to children, offering opportunities for younger participants to engage in research that could benefit their age group.

For individuals without a specific medical condition, there are significant opportunities to contribute. As mentioned, 1 of the new trials this month is actively seeking healthy volunteers. Across New Jersey, a total of 131 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Industry sponsors are driving a substantial portion of the new research efforts, accounting for 4 of the new trials this month. Notable industry sponsors include Novo Nordisk A/S, Novartis Pharmaceuticals, Tarsus Pharmaceuticals, Inc., and Minerva Neurosciences. Academic and other sponsors, such as Memorial Sloan Kettering Cancer Center and Maya Guglin, MD, are also contributing to the state's research landscape.

As we move further into May, residents are encouraged to explore these new and closing opportunities, contributing to the advancement of medical knowledge and potentially benefiting from cutting-edge treatments. The ongoing research in New Jersey promises to address a broad spectrum of health challenges in the months ahead.